FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Study on Physician Use of Off-label Unsupportive Data

A new study about the influence of data disclosures on physician decisions about off-label uses suggests that there is limited awareness of, and expos...

FDA General

FDA Needs Procedures for Reporting Political Interference: GAO

A new Government Accountability Office report recommends that FDA and other HHS agencies develop procedures for reporting and addressing allegations o...

Human Drugs

FDA Rejects Teva/MedinCell Risperidone NDA

FDA issues Teva Pharmaceuticals and MedinCell a complete response letter on their NDA for TV-46000/mdc-IRM (risperidone extended-release injectable su...

Federal Register

NCTR Science Advisory Board Panel Meeting

Federal Register notice: FDA announces a 5/18-19 meeting of the Science Advisory Board to the National Center for Toxicological Research (NCTR) Adviso...

Human Drugs

12 Warning Letters Sent to Skin Bleaching Marketers

Based on adverse events received, FDA sends Warning Letters to 12 companies for selling unapproved over-the-counter products intended to bleach or lig...

Marketing

Drug Companies Must Assume Messaging Risks: Attorneys

Two Arnall Golden Gregory attorneys recommend that drug companies keep all FDA promotion regulations in mind when they craft consumer and professional...

Biologics

Regenerative Stem Cell Institute Unapproved Cell Products

FDA says the Elgin-IL-based Regenerative Stem Cell Institute is marketing cellular products without an approved BLA or IND.

Biologics

High Bar for Vaccine Liability Claims

Three Morrison Foerster attorneys say a recent Connecticut federal court decision in a case involving Mercks Gardasil demonstrates there is a high bar...

Human Drugs

Closer Drug Postapproval Monitoring Needed: Researchers

Harvard Medical School researchers say FDA should clearly indicate when it has extrapolated an approved drug indication from pivotal trial data.

Human Drugs

No CDER Objection to Covis Materials for Makena Hearing

CDER says it doesnt object to additional materials Covis Pharma wants to introduce at a hearing on the FDA proposal to withdraw approval for Makena bu...